ABCL vs NOMA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Momentum & Technical, Options & Structure while NOMA counters with relative strength in Growth & Margin. Fundamentally, ABCL trades at 27.6x Forward P/E with -298.0% operating margin (+18.8% YoY revenue) versus NOMA at N/M Forward P/E and -164.5% operating margin (+122.9% YoY). In options structure, ABCL sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against NOMA sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABCL | NOMA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.6B | $22.3M | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | +18.8% | +122.9% | Higher Growth | NOMA |
| Operating Margin (TTM) Profitability | -298.0% | -164.5% | Higher Margin | NOMA |
| Net Profit Margin Profitability | -218.6% | -213.9% | Higher Margin | NOMA |
| Return on Equity (ROE) Capital Efficiency | -14.6% | -40.7% | Higher ROE | ABCL |
| 52-Week Range Position Momentum | 63% ($3โ$15) | 3% ($1โ$10) | Stronger Trend | ABCL |
| Beta / 30D Volatility Risk Regime | 2.30ฮฒ ยท 85% Vol | -0.45ฮฒ ยท 156% Vol | Lower Realized Risk | ABCL |
| Unified Institutional Score Composite Signal | 58.6 / 100 (HOLD) | 49.5 / 100 (HOLD) | Higher Composite | ABCL |